• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

碳酸酐酶 IX（CAIX）与乳腺癌患者生存的关系：系统评价和荟萃分析。

The relationship between carbonic anhydrase IX (CAIX) and patient survival in breast cancer: systematic review and meta-analysis.

机构信息

Academic Unit of Surgery, School of Medicine, University of Glasgow, Royal Infirmary, Alexandria Parade, Glasgow, G31 2ER, UK.

Unit of Molecular Pathology, School of Cancer Sciences, University of Glasgow, Wolfson Wohl Cancer Research Centre, Garscube Estate, Switchback Road, Glasgow, G61 1QH, UK.

出版信息

Diagn Pathol. 2023 Apr 15;18(1):46. doi: 10.1186/s13000-023-01325-9.

DOI:10.1186/s13000-023-01325-9
PMID:37061698
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10105416/
Abstract

PURPOSE

Hypoxia is a characteristic of many solid tumours and an adverse prognostic factor for cancer therapy. Hypoxia results in upregulation of carbonic anhydrase IX (CAIX) expression, a pH-regulating enzyme. Many human tissue studies have examined the prognostic value of CAIX expression in breast cancer but have yielded inconsistent results. Therefore, a systematic review and meta-analysis was undertaken to assess the prognostic value of CAIX expression for breast cancer patients.

METHODS

The electronic databases were systematically searched to identify relevant papers. The clinical outcomes included disease-free survival (DFS), recurrence-free survival (RFS) and overall survival (OS) in breast cancer patients. Review Manager version 5.4 was employed to analysis data from 23 eligible studies (containing 8390 patients).

RESULTS

High CAIX expression was associated with poorer RFS [HR = 1.42, 95% CI (1.32-1.51), p < 0.00001], DFS [HR = 1.64, 95% CI (1.34-2.00), p < 0.00001], and OS [HR = 1.48, 95% CI (1.22-1.80), p < 0.0001]. Heterogeneity was observed across the studies. There was an effect of the CAIX antibody employed, scoring methods, and tumour localisation on CAIX expression.

CONCLUSION

CAIX overexpression was significantly associated with poorer RFS, DFS, and OS in breast cancer patients. However, further work in high quantity tissue cohorts is required to define the optimal methodological approach.

摘要

目的

缺氧是许多实体瘤的特征，也是癌症治疗的不利预后因素。缺氧导致碳酸酐酶 IX（CAIX）表达上调，这是一种调节 pH 值的酶。许多人体组织研究都检查了 CAIX 表达在乳腺癌中的预后价值，但结果不一致。因此，进行了系统评价和荟萃分析，以评估 CAIX 表达对乳腺癌患者的预后价值。

方法

系统搜索电子数据库以确定相关文献。临床结局包括乳腺癌患者的无病生存率（DFS）、无复发生存率（RFS）和总生存率（OS）。使用 Review Manager 版本 5.4 分析来自 23 项合格研究（包含 8390 名患者）的数据。

结果

CAIX 高表达与较差的 RFS [HR=1.42，95%CI（1.32-1.51），p<0.00001]、DFS [HR=1.64，95%CI（1.34-2.00），p<0.00001]和 OS [HR=1.48，95%CI（1.22-1.80），p<0.0001]相关。研究之间存在异质性。CAIX 抗体的使用、评分方法和肿瘤定位对 CAIX 表达有影响。

结论

CAIX 过表达与乳腺癌患者的 RFS、DFS 和 OS 较差显著相关。然而，需要在高质量的组织队列中进行进一步的工作，以确定最佳的方法学方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/74cc/10105416/f0fbbbfbf474/13000_2023_1325_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/74cc/10105416/82dd347117eb/13000_2023_1325_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/74cc/10105416/fc90edeb81b3/13000_2023_1325_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/74cc/10105416/b3bf2942df13/13000_2023_1325_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/74cc/10105416/3ea6cb1adb5d/13000_2023_1325_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/74cc/10105416/f0fbbbfbf474/13000_2023_1325_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/74cc/10105416/82dd347117eb/13000_2023_1325_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/74cc/10105416/fc90edeb81b3/13000_2023_1325_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/74cc/10105416/b3bf2942df13/13000_2023_1325_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/74cc/10105416/3ea6cb1adb5d/13000_2023_1325_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/74cc/10105416/f0fbbbfbf474/13000_2023_1325_Fig5_HTML.jpg

相似文献

1
The relationship between carbonic anhydrase IX (CAIX) and patient survival in breast cancer: systematic review and meta-analysis.碳酸酐酶 IX（CAIX）与乳腺癌患者生存的关系：系统评价和荟萃分析。
Diagn Pathol. 2023 Apr 15;18(1):46. doi: 10.1186/s13000-023-01325-9.
2
Carbonic anhydrase IX promotes tumor growth and necrosis in vivo and inhibition enhances anti-VEGF therapy.碳酸酐酶 IX 促进体内肿瘤生长和坏死，抑制其活性可增强抗血管内皮生长因子治疗效果。
Clin Cancer Res. 2012 Jun 1;18(11):3100-11. doi: 10.1158/1078-0432.CCR-11-1877. Epub 2012 Apr 12.
3
The relationship between hypoxia-inducible factor 1α (HIF-1α) and patient survival in breast cancer: Systematic review and meta-analysis.缺氧诱导因子 1α（HIF-1α）与乳腺癌患者生存的关系：系统评价和荟萃分析。
Crit Rev Oncol Hematol. 2021 Mar;159:103231. doi: 10.1016/j.critrevonc.2021.103231. Epub 2021 Jan 19.
4
Platinum-containing regimens for metastatic breast cancer.转移性乳腺癌的含铂方案。
Cochrane Database Syst Rev. 2017 Jun 23;6(6):CD003374. doi: 10.1002/14651858.CD003374.pub4.
5
Systemic treatments for metastatic cutaneous melanoma.转移性皮肤黑色素瘤的全身治疗
Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2.
6
Optimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second malignant neoplasms, overall and progression-free survival: individual participant data analysis.未治疗的霍奇金淋巴瘤患者化疗和放疗在第二原发性恶性肿瘤、总生存期和无进展生存期方面的优化：个体参与者数据分析
Cochrane Database Syst Rev. 2017 Sep 13;9(9):CD008814. doi: 10.1002/14651858.CD008814.pub2.
7
Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.利用预后信息为乳腺癌患者选择辅助性全身治疗的成本效益
Health Technol Assess. 2006 Sep;10(34):iii-iv, ix-xi, 1-204. doi: 10.3310/hta10340.
8
Bisphosphonates and other bone agents for breast cancer.用于乳腺癌的双膦酸盐及其他骨治疗药物。
Cochrane Database Syst Rev. 2017 Oct 30;10(10):CD003474. doi: 10.1002/14651858.CD003474.pub4.
9
Treatment options for progression or recurrence of glioblastoma: a network meta-analysis.治疗胶质母细胞瘤进展或复发的选择：网络荟萃分析。
Cochrane Database Syst Rev. 2021 May 4;5(1):CD013579. doi: 10.1002/14651858.CD013579.pub2.
10
The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.卡莫司汀植入剂与替莫唑胺治疗新诊断的高级别胶质瘤的有效性和成本效益：一项系统评价与经济学评估
Health Technol Assess. 2007 Nov;11(45):iii-iv, ix-221. doi: 10.3310/hta11450.

引用本文的文献

1
Lymphadenectomy in upper tract urothelial carcinoma: Clinical insights and controversies (Review).上尿路尿路上皮癌的淋巴结清扫术：临床见解与争议（综述）
Oncol Rep. 2025 Nov;54(5). doi: 10.3892/or.2025.8970. Epub 2025 Aug 14.
2
Tumor Hypoxia: How Conventional Histology Is Reshaped in Breast Carcinoma.肿瘤缺氧：乳腺癌中传统组织学是如何重塑的。
Int J Mol Sci. 2025 May 6;26(9):4423. doi: 10.3390/ijms26094423.
3
Potential Benefits of Adding Alendronate, Celecoxib, Itraconazole, Ramelteon, and Simvastatin to Endometrial Cancer Treatment: The EC5 Regimen.

本文引用的文献

1
The Relationship Between the Tumor Cell Expression of Hypoxic Markers and Survival in Patients With ER-positive Invasive Ductal Breast Cancer.ER 阳性浸润性导管乳腺癌患者肿瘤细胞缺氧标志物表达与生存的关系。
J Histochem Cytochem. 2022 Jul;70(7):479-494. doi: 10.1369/00221554221110280. Epub 2022 Jul 6.
2
The relationship between hypoxia-inducible factor 1α (HIF-1α) and patient survival in breast cancer: Systematic review and meta-analysis.缺氧诱导因子 1α（HIF-1α）与乳腺癌患者生存的关系：系统评价和荟萃分析。
Crit Rev Oncol Hematol. 2021 Mar;159:103231. doi: 10.1016/j.critrevonc.2021.103231. Epub 2021 Jan 19.
3
在子宫内膜癌治疗中添加阿仑膦酸钠、塞来昔布、伊曲康唑、雷美替胺和辛伐他汀的潜在益处：EC5方案
Curr Issues Mol Biol. 2025 Feb 26;47(3):153. doi: 10.3390/cimb47030153.
4
Mapping molecular landscapes in triple-negative breast cancer: insights from spatial transcriptomics.三阴性乳腺癌分子图谱绘制：空间转录组学的见解
Naunyn Schmiedebergs Arch Pharmacol. 2025 Mar 22. doi: 10.1007/s00210-025-04057-3.
5
A series of benzensulfonamide derivatives as new potent carbonic anhydrase IX and XII inhibitors.一系列作为新型高效碳酸酐酶IX和XII抑制剂的苯磺酰胺衍生物。
Future Med Chem. 2025 Feb;17(3):271-285. doi: 10.1080/17568919.2025.2453420. Epub 2025 Jan 29.
6
Carbonic Anhydrase IX Enzyme in Triple Negative Breast Carcinoma: Relationship With Prognostic Factors and Response to Neoadjuvant Chemotherapy.三阴性乳腺癌中的碳酸酐酶IX：与预后因素及新辅助化疗反应的关系
Eur J Breast Health. 2025 Jan 1;21(1):57-62. doi: 10.4274/ejbh.galenos.2024.2024-6-1.
7
Elucidation of Dysregulated Pathways Associated With Hypoxia in Oestrogen Receptor-Negative Breast Cancer.雌激素受体阴性乳腺癌中与缺氧相关的失调通路的阐释
Cancer Med. 2024 Dec;13(23):e70274. doi: 10.1002/cam4.70274.
8
Lymph Node Dissection in Upper Tract Urothelial Carcinoma: Current Status and Future Perspectives.上尿路尿路上皮癌的淋巴结清扫术：现状与未来展望。
Curr Oncol Rep. 2023 Nov;25(11):1327-1344. doi: 10.1007/s11912-023-01460-y. Epub 2023 Oct 6.
CAIX is a predictor of pathological complete response and is associated with higher survival in locally advanced breast cancer submitted to neoadjuvant chemotherapy.
CAIX 是病理完全缓解的预测因子，与接受新辅助化疗的局部晚期乳腺癌患者的更高生存率相关。
BMC Cancer. 2019 Dec 3;19(1):1173. doi: 10.1186/s12885-019-6353-2.
4
Cancer statistics, 2019.癌症统计数据，2019 年。
CA Cancer J Clin. 2019 Jan;69(1):7-34. doi: 10.3322/caac.21551. Epub 2019 Jan 8.
5
Hypoxia-Inducible Factors and Cancer.缺氧诱导因子与癌症
Curr Sleep Med Rep. 2017 Mar;3(1):1-10. doi: 10.1007/s40675-017-0062-7. Epub 2017 Jan 28.
6
Apoptosis regulator Bcl-2 is an independent prognostic marker for worse overall survival in triple-negative breast cancer patients.凋亡调节因子Bcl-2是三阴性乳腺癌患者总生存期较差的独立预后标志物。
Int J Biol Markers. 2018 Jan;33(1):109-115. doi: 10.5301/ijbm.5000291.
7
The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy.缺氧在癌症进展、血管生成、转移及治疗抵抗中的作用。
Hypoxia (Auckl). 2015 Dec 11;3:83-92. doi: 10.2147/HP.S93413. eCollection 2015.
8
Overexpression of HIF1α and CAXI predicts poor outcome in early-stage triple negative breast cancer.缺氧诱导因子1α（HIF1α）和碳酸酐酶IX（CAXI）的过表达预示早期三阴性乳腺癌预后不良。
Virchows Arch. 2016 Aug;469(2):183-90. doi: 10.1007/s00428-016-1953-6. Epub 2016 May 16.
9
Evaluation of CAIX and CAXII Expression in Breast Cancer at Varied O2 Levels: CAIX is the Superior Surrogate Imaging Biomarker of Tumor Hypoxia.不同氧水平下乳腺癌中CAIX和CAXII表达的评估：CAIX是肿瘤缺氧的 superior 替代成像生物标志物。 注：“superior”在这里直接保留英文未翻译，可能是因为它在特定语境中有特定含义或专业术语用法，需要结合更多背景信息准确理解其确切意思。如果它是指“更好的、更优越的”等常规意思，可翻译为“更好的替代成像生物标志物” 。
Mol Imaging Biol. 2016 Apr;18(2):219-31. doi: 10.1007/s11307-015-0885-x.
10
Evaluation of carbonic anhydrase IX as a therapeutic target for inhibition of breast cancer invasion and metastasis using a series of in vitro breast cancer models.使用一系列体外乳腺癌模型评估碳酸酐酶IX作为抑制乳腺癌侵袭和转移的治疗靶点。
Oncotarget. 2015 Sep 22;6(28):24856-70. doi: 10.18632/oncotarget.4498.